Targeting Voltage-Gated Calcium Channels for Neuropathic Pain Management

Neurotherapeutics

Volumn 6, Issue 4, 2009, Pages 679-692

  Perret, Danielle ^a   Luo, Z David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

analgesics; Chronic; neuropathic pain; voltage gated calcium channels

Indexed keywords

AMLODIPINE; DILTIAZEM; EPERISONE; GABAPENTIN; GABAPENTIN ENACARBIL; LAMOTRIGINE; NIFEDIPINE; NIMODIPINE; OMEGA CONOTOXIN MVIIA; OPIATE; PLACEBO; PREGABALIN; QUETIAPINE; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

ABNORMAL THINKING; AMNESIA; ANALGESIA; ANOREXIA; ANXIETY; APPETITE; ARTICLE; ASTHENIA; ATAXIA; BLURRED VISION; CONFUSION; CONSTIPATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DYSARTHRIA; DYSGEUSIA; DYSPEPSIA; EDEMA; FEVER; FOOD AND DRUG ADMINISTRATION; GAIT; HEADACHE; HUMAN; INSOMNIA; LIMB PAIN; MEMORY DISORDER; MUSCLE SPASM; NAUSEA; NEUROPATHIC PAIN; NYSTAGMUS; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RIGOR; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SWEATING; TREMOR; URINE RETENTION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; CALCIUM CHANNELS; HUMANS; MEMBRANE TRANSPORT MODULATORS; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 70349449475     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.07.006     Document Type: Article

References (194)

1. Mitka M. "Virtual textbook" on pain developed: effort seeks to remedy gap in medical education. JAMA 290 (2003) 2395
2. Catterall W.A. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16 (2000) 521-555
3. Dolphin A.C. Beta subunits of voltage-gated calcium channels. J Bioenerg Biomembr 35 (2003) 599-620
4. Dolphin A.C. Beta subunits of voltage-gated calcium channels. J Bioenerg Biomembr 35 (2003) 599-620
5. Klugbauer N., Lacinova L., Marais E., Hobom M., and Hofmann F. Molecular diversity of the calcium channel a2d subunit. J Neurosci 19 (1999) 684-691
6. Qin N., Yagel S., Momplaisir M.L., Codd E.E., and D'Andrea M.R. Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. Mol Pharmacol 62 (2002) 485-496
7. Marais E., Klugbauer N., and Hofmann F. Calcium channel alpha2delta subunits-structure and gabapentin binding. Mol Pharmacol 59 (2001) 1243-1248
8. Kim H.L., Kim H., Lee P., King R.G., and Chin H. Rat brain expresses an alternatively spliced form of the dihydropyridine-sensitive L-type calcium channel alpha 2 subunit. Proc Natl Acad Sci U S A 89 (1992) 3251-3255
9. Angelotti T., and Hofmann F. Tissue-specific expression of splice variants of the mouse voltage-gated calcium channel alpha2/delta subunit. Febs Letters 397 (1996) 331-337
10. Ellis S.B., Williams M.E., Ways N.R., et al. Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science 241 (1988) 1661-1664
11. De Jongh K.S., Warner C., and Catterall W.A. Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene. J Biol Chem 265 (1990) 14738-14741
12. Brickley K., Campbell V., Berrow N., et al. Use of site-directed antibodies to probe the topography of the alpha 2 subunit of voltage-gated Ca2+ channels. Febs Letters 364 (1995) 129-133
13. Gurnett C.A., De Waard M., and Campbell K.P. Dual function of the voltage-dependent Ca2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron 16 (1996) 431-440
14. Wiser O., Trus M., Tobi D., Halevi S., Giladi E., and Atlas D. The alpha 2/delta subunit of voltage sensitive Ca2+ channels is a single transmembrane extracellular protein which is involved in regulated secretion. Febs Letters 379 (1996) 15-20
15. Mikami A., Imoto K., Tanabe T., et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 340 (1989) 230-233
16. Mori Y., Friedrich T., Kim M.S., et al. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature 350 (1991) 398-402
17. Hullin R., Singer-Lahat D., Freichel M., et al. Calcium channel beta subunit heterogeneity: functional expression of cloned cDNA from heart, aorta and brain. Embo J 11 (1992) 885-890
18. Williams M.E., Feldman D.H., McCue A.F., et al. Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron 8 (1992) 71-84
19. Brust P.F., Simerson S., McCue A.F., et al. Human neuronal voltage-dependent calcium channels: studies on subunit structure and role in channel assembly. Neuropharmacology 32 (1993) 1089-1102
20. Kang M.G., Felix R., and Campbell K.P. Long-term regulation of voltage-gated Ca(2+) channels by gabapentin. FEBS Lett 528 (2002) 177-182
21. Gurnett C.A., Felix R., and Campbell K.P. Extracellular interaction of the voltage-dependent Ca2+ channel alpha2delta and alpha1 subunits. J Biol Chem 272 (1997) 18508-18512
22. Wolf M., Eberhart A., Glossmann H., Striessnig J., and Grigorieff N. Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy. J Mol Biol 332 (2003) 171-182
23. Bauer C.S., Simerson S., McCue A.F., et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 29 (2009) 4076-4088
24. Hendrich J., Van Minh A.T., Heblich F., et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A 105 (2008) 3628-3633
25. Takahashi M., Seagar M.J., Jones J.F., Reber B.F., and Catterall W.A. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. Proc Natl Acad Sci U S A 84 (1987) 5478-5482
26. Catterall W.A. Structure and function of voltage-sensitive ion channels. Science 242 (1988) 50-61
27. Catterall W.A. Functional subunit structure of voltage-gated calcium channels. Science 253 (1991) 1499-1500
28. Black III J.L., and Lennon V.A. Identification and cloning of putative human neuronal voltage-gated calcium channel gamma-2 and gamma-3 subunits: neurologic implications. Mayo Clin Proc 74 (1999) 357-361
29. Kang M.G., Chen C.C., Felix R., et al. Biochemical and biophysical evidence for gamma 2 subunit association with neuronal voltage-activated Ca2+ channels. J Biol Chem 276 (2001) 32917-32924
30. Klugbauer N., Dai S., Specht V., et al. A family of gamma-like calcium channel subunits. FEBS Lett 470 (2000) 189-197
31. Letts V.A., Felix R., Biddlecome G.H., et al. The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit. Nat Genet 19 (1998) 340-347
32. Moss F.J., Viard P., Davies A., et al. The novel product of a five-exon stargazin-related gene abolishes Ca(V)2.2 calcium channel expression. Embo J 21 (2002) 1514-1523
33. Ertel E.A., Campbell K.P., Harpold M.M., et al. Nomenclature of voltage-gated calcium channels. Neuron 25 (2000) 533-535
34. Jan L.Y., and Jan Y.N. Voltage-sensitive ion channels. Cell 56 (1989) 13-25
35. Spedding M., and Lepagnol J. Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Biochem Soc Trans 23 (1995) 633-636
36. Tsien R.W., Ellinor P.T., and Horne W.A. Molecular diversity of voltage-dependent Ca2+ channels. Trends Pharmacol Sci 12 (1991) 349-354
37. Finkbeiner S., and Greenberg M.E. Ca2+ channel-regulated neuronal gene expression. J Neurobiol 37 (1998) 171-189
38. Belardetti F., and Zamponi G.W. Linking calcium-channel isoforms to potential therapies. Curr Opin Investig Drugs 9 (2008) 707-715
39. Davies J.N., and Zamponi G.W. Old proteins, developing roles: the regulation of calcium channels by synaptic proteins. Channels (Austin) 2 (2008) 130-138
40. Zamponi G.W., Lewis R.J., Todorovic S.M., Arneric S.P., and Snutch T.P. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 60 (2009) 84-89
41. Catterall W.A., Dib-Hajj S., Meisler M.H., and Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 28 (2008) 11768-11777
42. Yaksh T.L. Calcium channels as therapeutic targets in neuropathic pain. J Pain 7 (2006) S13-S30
43. McGivern J.G., and McDonough S.I. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 3 (2004) 457-478
44. Bourinet E., and Zamponi G.W. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem 5 (2005) 539-546
45. Schroeder C.I., Doering C.J., Zamponi G.W., and Lewis R.J. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med Chem 2 (2006) 535-543
46. Kisilevsky A.E., and Zamponi G.W. Presynaptic calcium channels: structure, regulators, and blockers. Handb Exp Pharmacol (2008) 45-75
47. Catterall W.A., and Few A.P. Calcium channel regulation and presynaptic plasticity. Neuron 59 (2008) 882-901
48. Fuchs A., Rigaud M., Sarantopoulos C.D., Filip P., and Hogan Q.H. Contribution of calcium channel subtypes to the intracellular calcium signal in sensory neurons: the effect of injury. Anesthesiology 107 (2007) 117-127
49. Diaz A., and Dickenson A.H. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 69 (1997) 93-100
50. Matthews E.A., and Dickenson A.H. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92 (2001) 235-246
51. Matthews E.A., and Dickenson A.H. Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 415 (2001) 141-149
52. Vanegas H., and Schaible H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85 (2000) 9-18
53. Westenbroek R.E., Hell J.W., Warner C., Dubel S.J., Snutch T.P., and Catterall W.A. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron 9 (1992) 1099-1115
54. Kerr L.M., Filloux F., Olivera B.M., Jackson H., and Wamsley J.K. Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur J Pharmacol 146 (1988) 181-183
55. Gohil K., Bell J.R., Ramachandran J., and Miljanich G.P. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 653 (1994) 258-266
56. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 80 (2006) 53-83
57. Bourinet E., Soong T.W., Stea A., and Snutch T.P. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A 93 (1996) 1486-1491
58. Altier C., and Zamponi G.W. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25 (2004) 465-470
59. Chaplan S.R., Pogrel J.W., and Yaksh T.L. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 269 (1994) 1117-1123
60. Maggi C.A., Tramontana M., Cecconi R., and Santicioli P. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in guinea pigs. Neurosci Lett 114 (1990) 203-206
61. Santicioli P., Del Bianco E., Tramontana M., Geppetti P., and Maggi C.A. Release of calcitonin gene-related peptide like-immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci Lett 136 (1992) 161-164
62. Evans A.R., Nicol G.D., and Vasko M.R. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res 712 (1996) 265-273
63. Saegusa H., Kurihara T., Zong S., et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. Embo J 20 (2001) 2349-2356
64. Saegusa H., Matsuda Y., and Tanabe T. Effects of ablation of N- and R-type Ca(2+) channels on pain transmission. Neurosci Res 43 (2002) 1-7
65. Hatakeyama S., Wakamori M., Ino M., et al. Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport 12 (2001) 2423-2427
66. Bell T.J., Thaler C., Castiglioni A.J., Helton T.D., and Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 41 (2004) 127-138
67. Lin Y., McDonough S.I., and Lipscombe D. Alternative Splicing in the voltage-sensing region of N-type CaV2.2 channels modulates channel kinetics. J Neurophysiol 92 (2004) 2820-2830
68. Lin Z., Haus S., Edgerton J., and Lipscombe D. Identification of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron 18 (1997) 153-166
69. Miljanich G.P. Venoms to drugs (2005). http://www.venomstodrugs.com/index.html?page=107301&pid=0 Heron Island, Australia. Available at: http://www.venomstodrugs.com/index.html?page=107301&pid=0
70. Hillyard D.R., Monje V.D., Mintz I.M., et al. A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron 9 (1992) 69-77
71. Lewis R.J., Nielsen K.J., Craik D.J., et al. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 275 (2000) 35335-35344
72. Nadasdi L., Yamashiro D., Chung D., Tarczy-Hornoch K., Adriaenssens P., and Ramachandran J. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry 34 (1995) 8076-8081
73. Smith M.T., Cabot P.J., Ross F.B., Robertson A.D., and Lewis R.J. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 96 (2002) 119-127
74. Wang Y.X., Gao D., Pettus M., Phillips C., and Bowersox S.S. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 84 (2000) 271-281
75. Wang Y.X., Pettus M., Gao D., Phillips C., and Scott Bowersox S. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 84 (2000) 151-158
76. Sluka K.A. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther 287 (1998) 232-237
77. Lynch S.S., Cheng C.M., and Yee J.L. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother 40 (2006) 1293-1300
78. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. Int J Clin Pharmacol Ther 44 (2006) 478-483
79. Wermeling D.P. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 25 (2005) 1084-1094
80. Atanassoff P.G., Hartmannsgruber M.W., Thrasher J., et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 25 (2000) 274-278
81. Mathur V.S. Ziconotide: a new pharmacological class of drug for the management of pain. Sem Anesth Periop Med Pain 19 (2000) 67-75
82. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291 (2004) 63-70
83. Wallace M.S., Charapata S.G., Fisher R., et al. Intrathecal Ziconotide in the treatment of chronic non-malignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9 (2006) 75-86
84. Lyseng-Williamson K.A., and Perry C. Ziconotide. CNS Drugs 20 (2006) 331-341
85. Rauck R.L., Wallace M.S., Leong M.S., et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 31 (2006) 393-406
86. Fisher R., Hassenbusch S., Krames E., et al. A consensus statement regarding the present suggested titration for prialt (ziconotide). Neuromodulation 8 (2005) 153-154
87. Saulino M. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Spinal Cord 45 (2007) 749-752
88. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291 (2004) 63-70
89. Snutch T.P. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2 (2005) 662-670
90. Wermeling D.P., and Berger J.R. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy 26 (2006) 395-402
91. Yarotskyy V., and Elmslie K.S. Omega-conotoxin GVIA alters gating charge movement of N-type (CaV2.2) calcium channels. J Neurophysiol 101 (2009) 332-340
92. Thompson J.C., Dunbar E., and Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 9 (2006) 147-152
93. Vitale V., Battelli D., Gasperoni E., and Monachese N. Intrathecal therapy with ziconotide: clinical experience and considerations on its use. Minerva Anestesiol 74 (2008) 727-733
94. Deer T., Krames E.S., Hassenbusch S.J., et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 10 (2007) 300-328
95. Smith H.S., Deer T.R., Staats P.S., Singh V., Sehgal N., and Cordner H. Intrathecal drug delivery. Pain Physician 11 (2008) S89-S104
96. Pin J.P., and Bockaert J. Omega-conotoxin GVIA and dihydropyridines discriminate two types of Ca2+ channels involved in GABA release from striatal neurons in culture. Eur J Pharmacol 188 (1990) 81-84
97. Zhang S.P., Kauffman J., Yagel S.K., and Codd E.E. High-throughput screening for N-type calcium channel blockers using a scintillation proximity assay. J Biomol Screen 11 (2006) 672-677
98. Scott D.A., Wright C.E., and Angus J.A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 451 (2002) 279-286
99. Malmberg A.B., and Yaksh T.L. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 60 (1995) 83-90
100. Cousins M., Goucke R., Cher L., and Brooker C. A phase I clinical trial of AM336, a novel N-type calcium channel blocker. IASP Press: 10th World Congress on Pain 200 (2002) 615-P249
101. Knutsen L.J., Hobbs C.J., Earnshaw C.G., et al. Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett 17 (2007) 662-667
102. Herlitze S., Garcia D.E., Mackie K., Hille B., Scheuer T., and Catterall W.A. Modulation of Ca2+ channels by G-protein beta gamma subunits. Nature 380 (1996) 258-262
103. Pirec V., Laurito C.E., Lu Y., and Yeomans D.C. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg 92 (2001) 239-243
104. Martin T.J., and Eisenach J.C. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 299 (2001) 811-817
105. Sharpe I.A., Gehrmann J., Loughnan M.L., et al. Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat Neurosci 4 (2001) 902-907
106. Paczkowski F.A., Sharpe I.A., Dutertre S., and Lewis R.J. chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem 282 (2007) 17837-17844
107. Nelson M.T., Joksovic P.M., Perez-Reyes E., and Todorovic S.M. The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors. J Neurosci 25 (2005) 8766-8775
108. Todorovic S.M., and Jevtovic-Todorovic V. The role of T-type calcium channels in peripheral and central pain processing. CNS Neurol Disord Drug Targets 5 (2006) 639-653
109. Sekizawa S.I., French A.S., and Torkkeli P.H. Low-voltage-activated calcium current does not regulate the firing behavior in paired mechanosensory neurons with different adaptation properties. J Neurophysiol 83 (2000) 746-753
110. Jagodic M.M., Pathirathna S., Nelson M.T., et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 27 (2007) 3305-3316
111. Jagodic M.M., Pathirathna S., Joksovic P.M., et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 99 (2008) 3151-3156
112. Dogrul A., Gardell L.R., Ossipov M.H., Tulunay F.C., Lai J., and Porreca F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 105 (2003) 159-168
113. Flatters S.J., and Bennett G.J. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109 (2004) 150-161
114. Todorovic S.M., Meyenburg A., and Jevtovic-Todorovic V. Redox modulation of peripheral T-type Ca2+ channels in vivo: alteration of nerve injury-induced thermal hyperalgesia. Pain 109 (2004) 328-339
115. Todorovic S.M., Meyenburg A., and Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res 951 (2002) 336-340
116. Choi S., Na H.S., Kim J., et al. Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav 6 (2007) 425-431
117. Bourinet E., Alloui A., Monteil A., et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. Embo J 24 (2005) 315-324
118. Shin H.S., Cheong E.J., Choi S., Lee J., and Na H.S. T-type Ca2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol 8 (2008) 33-41
119. Todorovic S.M., Jevtovic-Todorovic V., Meyenburg A., et al. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron 31 (2001) 75-85
120. Todorovic S.M., and Jevtovic-Todorovic V. Regulation of T-type calcium channels in the peripheral pain pathway. Channels (Austin) 1 (2007) 238-245
121. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
122. Raskin P., Donofrio P.D., Rosenthal N.R., et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63 (2004) 865-873
123. Thienel U., Neto W., Schwabe S.K., and Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110 (2004) 221-231
124. Khoromi S., Patsalides A., Parada S., Salehi V., Meegan J.M., and Max M.B. Topiramate in chronic lumbar radicular pain. J Pain 6 (2005) 829-836
125. Fowler J.A., Shen J.Y., and Bettinger T.L. Successful use of topiramate in a patient with severe postherpetic neuralgia. Ann Pharmacother 43 (2009) 139-142
126. Chong M.S., and Libretto S.E. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 19 (2003) 59-68
127. Ophoff R.A., Terwindt G.M., Vergouwe M.N., et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87 (1996) 543-552
128. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 4 (2003) 386-398
129. Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics 4 (2007) 274-284
130. Murakami M., Nakagawasai O., Suzuki T., et al. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice. Brain Res 1024 (2004) 122-129
131. Luo Z.D., Chaplan S.R., Higuera E.S., et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21 (2001) 1868-1875
132. Luo Z.D., Calcutt N.A., Higuera E.S., et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303 (2002) 1199-1205
133. Newton R.A., Bingham S., Case P.C., Sanger G.J., and Lawson S.N. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 95 (2001) 1-8
134. Wang H., Sun H., Della Penna K., et al. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience 114 (2002) 529-546
135. Valder C.R., Liu J.J., Song Y.H., and Luo Z.D. Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. J Neurochem 87 (2003) 560-573
136. Li C.Y., Song Y.H., Higuera E.S., and Luo Z.D. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 24 (2004) 8494-8499
137. Gee N.S., Brown J.P., Dissanayake V.U., Offord J., Thurlow R., and Woodruff G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271 (1996) 5768-5776
138. Hwang J.H., and Yaksh T.L. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Regional Anesthesia 22 (1997) 249-256
139. Abdi S., Lee D.H., and Chung J.M. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 87 (1998) 1360-1366
140. Field M.J., McCleary S., Hughes J., and Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80 (1999) 391-398
141. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
142. Rosner H., Rubin L., and Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 12 (1996) 56-58
143. Rosenberg J.M., Harrell C., Ristic H., Werner R.A., and de Rosayro A.M. The effect of gabapentin on neuropathic pain. Clin J Pain 13 (1997) 251-255
144. Nudler S., Piriz J., Urbano F.J., Rosato-Siri M.D., Renteria E.S., and Uchitel O.D. Ca2+ channels and synaptic transmission at the adult, neonatal, and P/Q-type deficient neuromuscular junction. Ann N Y Acad Sci 998 (2003) 11-17
145. Perrier J.F., Alaburda A., and Hounsgaard J. Spinal plasticity mediated by postsynaptic L-type Ca2+ channels. Brain Res Brain Res Rev 40 (2002) 223-229
146. Westenbroek R.E., Hoskins L., and Catterall W.A. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 18 (1998) 6319-6330
147. Kato A., Ohkubo T., and Kitamura K. Algogen-specific pain processing in mouse spinal cord: differential involvement of voltage-dependent Ca(2+) channels in synaptic transmission. Br J Pharmacol 135 (2002) 1336-1342
148. Reid C.A., Bekkers J.M., and Clements J.D. Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci 26 (2003) 683-687
149. Talley E.M., Cribbs L.L., Lee J.H., Daud A., Perez-Reyes E., and Bayliss D.A. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci 19 (1999) 1895-1911
150. Lambert R.C., McKenna F., Maulet Y., et al. Low-voltage-activated Ca2+ currents are generated by members of the CavT subunit family (alpha1G/H) in rat primary sensory neurons. J Neurosci 18 (1998) 8605-8613
151. McCallum J.B., Kwok W.M., Mynlieff M., Bosnjak Z.J., and Hogan Q.H. Loss of T-type calcium current in sensory neurons of rats with neuropathic pain. Anesthesiology 98 (2003) 209-216
152. Boroujerdi A., Kim H.K., Lyu Y.S., et al. Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain (2008)
153. Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat 4 (2008) 1193-1201
154. Stahl S.M. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry 65 (2004) 596-597
155. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
156. Rice A.S., and Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94 (2001) 215-224
157. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., Schmidt B., and The International Gabapentin Study Group. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 35 (1994) 795-801
158. Garcia-Borreguero D., Larrosa O., de la Llave Y., Verger K., Masramon X., and Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59 (2002) 1573-1579
159. Pollack M.H., Matthews J., and Scott E.L. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155 (1998) 992-993
160. Bockbrader H. Clinical pharmacokinetics of gabapentin. Drugs Today 31 (1995) 613-619
161. McLean M.J. Clinical pharmacokinetics of gabapentin. Neurology 44 (1994) S17-S22 discussion S31-12
162. Stewart B.H., Kugler A.R., Thompson P.R., and Bockbrader H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10 (1993) 276-281
163. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 101 (2000) 359-371
164. Hemstreet B., and Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther 23 (2001) 520-531
165. Todorov A.A., Kolchev C.B., and Todorov A.B. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 21 (2005) 358-361
166. Arnold L.M., Goldenberg D.L., Stanford S.B., et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56 (2007) 1336-1344
167. Matthews E.A., and Dickenson A.H. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 96 (2002) 633-640
168. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., and Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005) 1324-1334
169. Hanna M., O'Brien C., and Wilson M.C. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 12 (2008) 804-813
170. Gu R., Gusler G.M., and Hou S.Y.E. Extended release and dose-proportionality of a novel gabapentin formulation (2006), The 88th Annual Meeting of the Endocrine Society 319 (abstract)
171. Gordi T., Hou E., Kasichayanula S., and Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 30 (2008) 909-916
172. Sabatowski R., Gálvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109 (2004) 26-35
173. Irving G., Jensen M., Cramer M., et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25 (2009) 185-192
174. Cundy K.C., Sastry S., Luo W., Zou J., Moors T.L., and Canafax D.M. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 48 (2008) 1378-1388
175. Kushida C.A., Becker P.M., Ellenbogen A.L., Canafax D.M., and Barrett R.W. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 72 (2009) 439-446
176. Gajraj N.M. Pregabalin: its pharmacology and use in pain management. Anesth Analg 105 (2007) 1805-1815
177. Dworkin R.H., and Kirkpatrick P. Pregabalin. Nat Rev Drug Discov 4 (2005) 455-456
178. Frampton J.E., and Foster R.H. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 65 (2005) 111-120
179. Gray P. Pregabalin in the management of central neuropathic pain. Expert Opin Pharmacother 8 (2007) 3035-3041
180. Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today 41 (2007) 509-516
181. Owen R.T. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc) 43 (2007) 857-863
182. Stacey B.R., and Swift J.N. Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep 10 (2006) 179-184
183. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
184. Calandre E.P., Morillas-Arques P., Rodriguez-Lopez C.M., Rico-Villademoros F., and Hidalgo J. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry 40 (2007) 68-71
185. Mease P.J., Russell I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514
186. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9 (2008) 792-805
187. Crofford L.J., Mease P.J., Simpson S.L., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136 (2008) 419-431
188. Recla J.M., and Sarantopoulos C.D. Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?. Med Hypotheses 73 (2009) 177-183
189. De Lange F.P., Knoop H., Bleijenberg G., Van der Meer J.W., Hagoort P., and Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 26 (2005) 777-781
190. Kuchinad A., Schweinhardt P., Seminowicz D.A., Wood P.B., Chizh B.A., and Bushnell M.C. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?. J Neurosci 27 (2007) 4004-4007
191. Okada T., Tanaka M., Kuratsune H., Watanabe Y., and Sadato N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol 4 (2004) 14
192. Schmidt-Wilcke T., Luerding R., Weigand T., et al. Striatal grey matter increase in patients suffering from fibromyalgia--a voxel-based morphometry study. Pain 132 suppl 1 (2007) S109-S116
193. Schmidt-Wilcke T., Leinisch E., Straube A., et al. Gray matter decrease in patients with chronic tension type headache. Neurology 65 (2005) 1483-1486
194. Villarreal G., Hamilton D.A., Petropoulos H., et al. Reduced hippocampal volume and total white matter volume in posttraumatic stress disorder. Biol Psychiatry 52 (2002) 119-125